KIT receptor, the c-kit gene product, is thought to play a major role in canine mastocytoma, one of the most common neoplastic diseases in dogs. In the present study, the expression of c-kit proto-oncogene in blood and in tumor biopsies from 41 dogs with histologically confirmed mastocytoma at different grades of cellular differentiation and 5 negative control dogs was investigated using real-time (quantitative) reverse transcription-polymerase chain reaction (RRT-PCR). The animals were followed up for over 1 year after surgery in order to characterize the kinetics of c-kit expression in blood. Transcript mRNAs extracted from blood at different time points after surgery and from tumor tissue surgically removed from each dog were used in a quantitative RRT-PCR assay targeting the extracellular coding region of the c-kit gene. Tissues constitutively expressing c-kit (brain and spleen) were used as positive controls. Levels of expression of c-kit were higher in tumor biopsies than in blood; the blood level decreased in the patients between 1 and 3 months after surgery. No KIT expression was detected in blood from the 5 dogs not affected by mastocytoma (negative controls). The RRT-PCR appears to be a suitable method for sensitive and quantitative detection of c-kit gene expression in canine blood and neoplastic tissues. Although c-kit expression levels measured by RRT-PCR do not correlate with prognosis, they confirm that surgery remains the main treatment to reduce circulating mastocytes and that circulating mast cells can be detected even in benign highly differentiated forms of mastocytoma such as grade I.
Introduction
Recent studies have revealed that altered c-kit levels occur in a variety of malignant neoplasms including mast cell tumors. 22 Mast cells are immune-specialized cells normally distributed throughout the body and functionally active in inflammation and allergy response. After stimulation they release histamine, heparin, serotonin, prostaglandins, and proteolytic enzymes.
In dogs, mast cell tumor or mastocytoma is one of the most common types of skin neoplasms, accounting for 16% to 21% of all skin tumors and 11% to 27% of all malignant skin tumors. 25 Most mastocytomas arise from the dermis and subcutaneous tissues; widely metastatic mastocytosis is not common (less than one-tenth that of cutaneous cases). Disseminated mastocytosis without an associated cutaneous mastocytoma is reported infrequently in dogs. 16 These tumors usually occur singly, but multiple cutaneous mast cell tumors have been reported in as many as 11% of canine mastocytoma patients. It is unclear whether multiple cutaneous mastocytomas represent metastases or are multicentric in origin. 4 The biologic behavior of mastocytomas is highly variable; some tumors have a benign behavior, whereas others exhibit aggressive growth and metastasize. 2 A number of different parameters have been described as predictors of the clinical behavior of canine mastocytoma, the most consistent of which are histologic grade and clinical stage. 17 In recent years, molecular parameters have been studied.
The proto-oncogene c-kit is known to play a critical role in mast cell development and tumors. 14 C-kit encodes the transmembrane receptor KIT, which is a type-III tyrosine kinase receptor, a protein consisting of an extracellular ligand-binding region (5 immunoglobulin-like domains), a single transmembrane spanning region (hydrophobic domain), and a cytoplasmic region. The cytoplasmic region includes both the kinase (adenosine triphosphate [ATP]binding and phosphotransferase) and the juxtamembrane domains. The specific ligand for KIT receptor is the stem cell factor (SCF), a cytokine that, among other functions, binds to the extracellular domain, causing receptor dimerization, which induces tyrosine autophosphorylation in the kinase domain and initiates multiple biologic response signaling pathways (proliferation, migration, and differentiation of mast cells, hematopoietic stem cells, germ cells, and melanocytes). 1, 11 This mechanism was first shown for human c-kit gene, which has been completely sequenced and well characterized. 6, 26, 28 High conservation in sequence has been reported for the c-kit gene within mammals despite the differences in biologic behavior of mastocytoma observed between humans and dogs. 14, 15 According to previous studies at least 2 mechanisms have been proposed for mast cell proliferation: ligand-dependent and ligand-independent. 1 Little data is available in canines for the ligand-dependent KIT activation, while in humans SCF expression level and availability have been shown to affect mast cell differentiation, activation, and proliferation. 3, 5, 11, 27 The ligand-independent mast cell proliferation in dogs, although not completely known, seems to be associated with at least 2 types of alterations. First, the overexpression of c-kit induces a constantly high level of KIT receptor activation 7, 13 ; second, mutations in vivo in the juxtamembrane and in vitro in the tyrosine kinase domains of c-kit induce constitutive phosphorylation of KIT receptor, which results in ligand-independent KIT activation and tumor development. 10, 12, 19 The significance of c-kit mutations as a predictor for clinical outcome is still unclear.
The present work was carried out to study the expression of c-kit mRNA, both in blood and in tissues from a large number of dogs with mast cell tumors, using quantitative real-time reverse transcription-polymerase chain reaction (RRT-PCR). The goal was to examine the potential usefulness of c-kit mRNA expression as a predictor of mastocytoma clinical behavior in comparison with traditional parameters such as histologic grade and/or clinical features. To accomplish this goal, 41 dogs with histologically confirmed mastocytoma at different grades of cellular differentiation and 5 negative controls were tested for c-kit mRNA expression levels over a period of 1 year using RRT-PCR.
Materials and methods

Study population, tissue specimens, and clinical data
This study was performed on a heterogeneous population of 41 confirmed cases of spontaneous canine cutaneous mastocytoma undergoing follow-up for over a year. Five dogs not affected by mast cell tumor were included in this study as negative controls.
All patients were enrolled in the study after registration of age, breed, gender, anamnesis, clinical signs, number of tumors, size, anatomical location (trunk, head/neck, perineal/inguinal region, and extremities), histologic grade (I, II, and III), and type of treatment (surgery, surgery and radiation therapy, surgery and chemotherapy, radioactiv-ity, or chemotherapy without surgery). In addition, local recurrence, regional or distant metastasis, and reason of death were also recorded.
Before admission to treatments, each dog underwent blood cell and platelet counts, and evaluation of serum biochemical parameters; complete tumor staging and characterization, including cytology of regional lymph node, buffy coat smear, thoracic radiographs, abdominal ultrasonographic, and, if necessary, percutaneous fineneedle aspirate cytology on all enlarged abdominal organs were also performed. In addition to mastocytoma-affected dogs, as positive controls, samples from the spleen and cerebellum (tissues constitutively expressing c-kit) were removed from a non-tumor-bearing dog immediately after euthanasia.
Total mRNA purification and cDNA synthesis
Extraction of total mRNA was performed on fresh blood at different time points after surgery and on biopsies surgically removed from each dog. Tumor tissue specimens were taken from the central part of the tumor mass, carefully avoiding margins and nonneoplastic surrounding tissue. Each specimen was aseptically minced into small pieces and handled with new disposable blades and gloves to avoid contamination.
Total mRNA was extracted from blood and homogenized tissues (rotor/stator system) with the 6100 Prep Station and Reagents. a Purified mRNA was reverse transcribed in cDNA by using the cDNA Retrotranscription Archive kit with random hexamers as primers. a
PCR amplification and relative quantification
The cDNA obtained from each sample was used as a template in RRT-PCR determinations, in optimized 20 ml reaction volume in MicroAmp optical 96-well plates. Each plate contained duplicates of each sample cDNA (9 ml), 2X Universal Master Mix (10 ml), a and 1 ml of Assay-by-Design primer and probe mix. All primers and probes (labeled with FAM and TAMRA fluorescent dyes) were designed using Primer Express Software purchased from Applied Biosystems. a The c-kit primer pair and Taqman probe were selected from the extracellular region (exons 7 and 8) of the published canine c-DNA c-kit sequence (accession number gi:32351485 gb:AY313776.1) in the GenBank database of the National Center for Biotechnology International (NCBI). C-kit was amplified with 59-TCAAGTGTCCAATTCCGATGTCAAT-39 (forward primer), 59-TGCCATTCGTGAGACTTTCATGAG-39 (reverse primer), and 59-CTGGTTTTGTGTTCACA-TAAA-39 (probe).
In order to quantify the efficiency of cDNA synthesis from extracted mRNA, a pair of primers and a probe to the canine housekeeping gene alpha-tubulin were also generated, through the Assay-by-Design software (sequence accession number gi:15911755 gb:BI817044.1 of NCBI). The alpha-tubulin amplification was obtained with 59-TTGTAGACCTGGAGCCCACAGT-39 (forward primer), 59-AGCTGCTCAGGGTGGAAGAG-39 (reverse primer), and 59-TGCGAACTTCATCAAT-39 (probe).
In addition to the cDNA samples, duplicates of 10-fold serial dilutions of a known amount of canine cerebellum cDNA were used as control templates to generate standard curves for estimation of the expression in relationship to the calibrator (cerebellum 1:10) (relative quantification). A duplicate no-template control (NTC) was also included in each plate.
The quantitative RRT-PCR was carried out in the 7000 Sequence Detection System a at the following thermal cycle conditions: 10 min at 95uC followed by 40 cycles of 15 sec at 95uC and 1 min at 60uC (2-step PCR). Quantification was achieved after application of an algorithm on the data analyzed by the software of the 7000 Detection System. a For each sample assayed, the expression level was calculated on the basis of the standard amplification curves produced in the same experiment. The canine c-kit expression was normalized on data calculated from alphatubulin cDNA expression (mean), amplified from the same sample and run in the same session. Automated DNA sequencing was obtained for each case as previously described by the same authors. 21 
Statistical analyses
Results of each cDNA sample analyzed were calculated from the arithmetic mean of 2 different experiments. The analysis of variance (ANOVA) test was used to compare the c-kit expression with tumor size, location, histologic grade, treatment, and survival.
Results
The time course of the study covered a period of 5 years (1999-2004) and included a total of 41 cases of canine mastocytoma and 5 negative control dogs. The panel of 41 mastocytomas consisted of 23 malignant tumors (grades of cellular differentiation II or III), 15 benign (grade I), and 3 with uncertain malignant potential (not histologically graded). The following breeds were affected: Boxer, English Setter, Beagle, Labrador Retriever, Rottweiler, Standard Schnauzer, American Staffordshire Terrier, Bull Terrier, Briard, Brittany Spaniel, German Shepherd Dog, Dachshund, Great Dane, Yorkshire Terrier, and mixed-breed dogs; these latter accounted for 34% (14 of 41) of cases. Twenty-three dogs were males (sexually intact or sterilized), and 18 were females (spayed or sexually intact). Median age was 9 years (range of 7 to 14 years), except for 7 younger animals aged from 2.5 to 5 years. Tumor location included the trunk, the head/neck region, the perineal/inguinal region, and the extremities. Seven dogs had multiple cutaneous mastocytomas, and 9 showed metastasis to their regional lymph nodes.
All dogs except 1 underwent surgical excision of the entire tumor, and the diagnosis of mastocytoma was confirmed by histologic analysis. According to histopathologic findings, tumors were classified as grade I in 15 dogs, as grade II in 17, and as grade III in 6 dogs. 17 Tissue histology was not obtained from 3 dogs.
Seventeen patients underwent chemotherapy with lomustine, prednisone, vinblastine, vincristine sulphate, and/or cyclophosphamide before or after surgical excision for up to 6 months; 1 was treated with radiation therapy. Ten patients died of other diseases (after 2-10 months); 7 were euthanized for progressive mastocytoma disease; 18 patients remained healthy; and 6 could not be followed up for the entire year. Three patients showed clinical signs of mastocytoma recurrence and underwent further surgery. One dog underwent radiation therapy without surgery. During the follow-up period, animals were controlled at different time points by measuring the magnitude of c-kit mRNA expression.
Treatment had almost no effect on reduction of circulating mast cells; no significant relationship was found between chemotherapy or radiation therapy (treatment protocol) and c-kit expression in blood along the time-course of the follow-up. Further details on clinicopathologic and follow-up data are given in Table 1 . For each case, the sequence of c-kit region (exons 9-13) was determined with the aim of identifying gene mutations. 21 In order to examine the expression of c-kit mRNA in canine mastocytoma, we performed RRT-PCR on RNA from blood at the time of surgical excision, 1, 3, 6, and 12 months later and on mRNA extracted from tumor mass of all clinical samples. Normal cerebellum and spleen biopsies were tested as well to determine the basal levels of c-kit expression (positive controls). The amplification was performed with a primer and probe set corresponding to exons 7 and 8 of the extracellular domain of the gene product. The level of c-kit transcript was reported as relative quantification compared with the calibrator (cerebellum mRNA, diluted 1 : 10) and standardized using the expression of the alpha-tubulin gene amplified from the same sample as internal reference (the expression of alpha-tubulin cDNA was positive in all the samples assayed).
As shown in Fig. 1 , c-kit expression was detected at a high level in mast cell tumor samples (biopsies). Although intensities varied for each case, the average expression of this gene in tumor tissue (T) reached a 4-fold higher level than the reference. The expression of c-kit mRNA was not detectable in the tumor mass of 8 cases.
The c-kit expression, strongly observed in tumor biopsies, was also detected in most blood specimens, although at lower levels. The c-kit expression in blood measured at the time of surgery (B0) was the highest detected in blood and reached about one tenth of the reference values. Kinetic results of the RRT-PCR tests, carried out on serial blood specimens collected over the entire year of follow-up, revealed a similar pattern of c-kit mRNA expression in blood for all the animals: c-kit transcript mRNA decreased consistently between 1 and 3 months after surgery (B1 and B3) and then remained persistently low. In 8 cases, c-kit mRNA could not be detected.
The c-kit gene expression was not significantly related to any of the parameters being evaluated: size and location of the tumor, histologic grade, treatment, and survival. Table 2 shows the average expression of c-kit in blood specimens, according to dog stratification for follow-up status. All the animals under study but one underwent surgery. For the only dog not to have undergone surgical excision (because of the presence of 20 small diffused mast cell tumors) data of c-kit mRNA expression are not available for late time points. In normal blood and skin from 2 healthy dogs (negative controls), c-kit expression was undetectable.
Discussion
It has been reported that altered levels of c-kit gene expression are associated with different types of malignant tumors, also including the canine masto- M  11  5  3  II  DOOD  22  Beagle  M  12  3  10  II/III  DOM  23  mix  F  9  2  8  II/III  DOM  24  mix  F  10  4  3  II/III  DOM  25  mix  M  13  2  2.5  III  DOOD  26  Beagle  M  14  6  3  III  DOOD  27  Briard  F  12  1/3  2/20  III  DOM  28  mix  F  10  1  UNK  UNK  NFU  29  mix  F  12  1  4  II  DOM  30 American Staffordshire Terrier II  NED  32  Boxer  M  4  5  3  I  NED  33  Boxer  M  6  5  1  I  NED  34  Bull Terrier  F  5  4  1.5  I  NED  35  Dachshund  F  4  1  0.5  I  NED  36  Great Dane  F  8  3  3  II  NED  37  mix  M cytoma. 22 The product of the proto-oncogene c-kit, the KIT protein, may therefore be used as a marker for diagnosis and prognosis. 18, 24 At present, prognostic and therapeutic determinations for mastocytomas are primarily based on the histologic grading of the tumor, which is highly questionable for intermediate grade. Alternatively, immunohistochemistry has been shown to be a valuable prognostic method when based on KIT-staining pattern. 8 Few reports are available to date on the use of PCR for quantification of c-kit expression, but nobody so far has used RRT-PCR or has carried out a kinetic study. London et al. used PCR and showed the expression of c-kit mRNA in mastocytoma biopsies; Kubo et al. detected high levels of c-kit transcription in mast cell tumors, by competitive-quantitative PCR, comparing them to those of normal spleen and mammary adenocarcinoma. 9, 13 The aim of the present study was to 1) assess the suitability of a RRT-PCR method for sensitive quantitative determination of c-kit gene expression in canine blood and neoplastic tissues, and 2) analyze the kinetic pattern of c-kit transcription in canine mastocytoma. The results obtained essentially agree with the decreased expression of c-kit mRNA observed after surgery. Detection of c-kit mRNA in blood could primarily be explained by the presence of circulating mast cells, possibly recruited by inflammatory stimuli or mobilized by a systemic disease.
In the present study, c-kit transcripts were detected in blood at the time of surgical excision in many cases although no circulating mastocytes could be detected upon cytologic examination of the same specimen. This may be explained in 2 ways. It is possible that most mast cell tumors express a significant level of ckit mRNA, although protein levels may be too low to be detected in immunohistochemical assay. Alternatively, it is possible that detected transcripts are not intact and that protein synthesis is truncated early. 23 A PCR-based method is ideal for fast and highly sensitive detection of molecular targets for diagnostic, prognostic, or therapy monitoring purposes. However, our study has not demonstrated a significant association between the level of c-kit expression and the biologic behavior of canine mast cell tumor ( Table 2) .
The results of the present study agree with previously published studies on cutaneous canine mastocytoma that have shown absence of a gender prevalence. 25 Little data is available from literature on the relationship between the level of KIT expression and dog mastocytoma grade or stadium; Reguera et al. observed by immunohistochemistry a reverse correlation between degree of differentiation and KIT expression in tumor tissue 20 ; however, to the authors' knowledge, no other investigators have carried out this sort of analysis on blood specimens or used the RRT-PCR method. Grade I mastocytomas Table 1 . On X-axis, samples are reported (T 5 expression of c-kit detected on tumor mass surgically removed; B0 5 expression of ckit in blood at time of surgery; B1 5 1 month after surgery, B3 5 3 months after surgery; B6 5 6 months after surgery; B12 5 1 year after surgery); Y-axis levels of c-kit expression (average of all the 41 cases) relative to the level of expression in cerebellum. PCR amplification of cDNA obtained from reverse transcription of total mRNA purified from mast cell tumors and blood specimens was performed in real time. Table 2 . Average c-kit expression in blood of 41 dogs, grouped according to follow-up at each time point. C-kit expression in blood was quantified using as a reference the expression level in cerebellum. PCR amplification of cDNA obtained from reverse transcription of total mRNA purified from blood specimens was performed in real-time. are usually considered benign tumors, highly differentiated, with regular nuclei and rare or no mitotic figures; and they appear to have a very good prognosis beyond surgical removal. Conversely, grade III tumors are undifferentiated, with large, misshapen nuclei and many mitotic figures; they are very aggressive and have a poor prognosis. Grade II tumors are moderately differentiated and have intermediate prognosis. 17 In our study, no correlations were found between c-kit expression in blood and the grade of the tumor or its degree of differentiation.
With regard to genetic predisposition (with respect to breed), the results herein agree with previous reports. More susceptible breeds, after mixed breeds, include Boxer first, followed by Labrador Retriever, Beagle, and English Setter, although no statistically significant association was seen between c-kit expression level and the dog breed. Nor were correlations found between c-kit expression and age.
The complexity and molecular diversity of canine mastocytoma may explain the high variability of biologic behavior of these tumors; further studies are required to understand the molecular mechanisms underlying the functional significance of c-kit expression pathway in mast cell proliferative disorders. Since dogs with diseases other than mast cell tumors were not included in this study, the effect of concurrent diseases on the level of c-kit expression cannot be excluded.
In conclusion, RRT-PCR was shown in this study to be a sensitive tool for quantitative determination of c-kit gene expression in canine blood and neoplastic tissues. The results, based on the magnitude of c-kit expression determined by means of RRT-PCR, although deficient in prognostic value, suggest that surgery remains the major treatment to reduce circulating mastocytes and that circulating mast cells can be also detected in benign highly differentiated forms of the tumor, classified as grade I. The major findings were 1) the presence of a detectable c-kit expression in blood at time of surgery, although no circulating mast cells had been cytologically detected; and 2) the observation of a decline in c-kit expression in blood within a few months after surgery. No correlations were found in this study between clinical/ histologic parameters and c-kit expression level in the mast cell tumor mass or blood; however, these results indicate the complexity and molecular diversity of canine mastocytoma, which may explain the high variability of biologic behavior of these tumors. Further studies are required for understanding the molecular mechanisms underlying KIT pathways and mast cell proliferative disorders.
